A Phase Ib Study of the combination of Aurora Kinase Inhibitor alisertib (MLN8237) and bortezomib in Relapsed or Refractory Multiple Myeloma

類似資料

• MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
  著者:: Sells, Todd B., 等
  出版事項: (2015)
• Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
  著者:: Falchook, Gerald S., 等
  出版事項: (2015)
• Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma(†)
  著者:: Dickson, M. A., 等
  出版事項: (2016)
• Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
  著者:: Kelly, Kevin R., 等
  出版事項: (2013)
• A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
  著者:: Gay, Carl M., 等
  出版事項: (2020)